Larimar Therapeutics (LRMR) Total Non-Current Liabilities (2013)
Larimar Therapeutics (LRMR) posted Total Non-Current Liabilities of -$100.9 million for Q4 2013.
Larimar Therapeutics (LRMR) Total Non-Current Liabilities (2013) Analysis & Trends
Larimar Therapeutics' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at -$100.9 million for Q4 2013.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to -$100.9 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was -$100.9 million (changed N/A YoY) and the FY2013 annual result came in at -$100.9 million, down 60.68% from the prior year.
- Total Non-Current Liabilities was -$100.9 million for Q4 2013 at Larimar Therapeutics.
- Across five years, Total Non-Current Liabilities topped out at -$100.9 million in Q4 2013 and bottomed at -$100.9 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | -100.88 Mn |